AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2835891 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 120
Study 2835891 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 120
Study 29340574 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 128
Study 29340574 — intervention group
Group type: COMPARATOR
Intervention: Conscious Sedation (CS)
Number of subjects: 128
Study 27838347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone treatment for 6 weeks
Number of subjects: 84
Study 27838347 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic asthma
Number of subjects: 84
Study 27838347 — intervention group
Group type: COMPARATOR
Intervention: Atopy but no asthma
Number of subjects: 84
Study 27838347 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 84
Study 26268314 — intervention group
Group type: EXPERIMENTAL
Intervention: PanAd3‐RSV vaccine
Number of subjects: 0
Study 26268314 — intervention group
Group type: EXPERIMENTAL
Intervention: PanAd3‐RSV vaccine in combination with MVA‐RSV
Number of subjects: 0
Study 26268314 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24048694 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal health budgets
Number of subjects: 2000
Study 24048694 — intervention group
Group type: COMPARATOR
Intervention: Conventional support arrangements (Control)
Number of subjects: 2000
Study 21924181 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 85
Study 18433614 — intervention group
Group type: EXPERIMENTAL
Intervention: EASI derived ECG
Number of subjects: 44
Study 18433614 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN derived ECG
Number of subjects: 44
Study 18433614 — intervention group
Group type: EXPERIMENTAL
Intervention: PS derived ECG
Number of subjects: 44
Study 15668336 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hydroxyethyl methacrylate (HEMA)
Number of subjects: 0
Study 12950124 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral catheterisation (18 patients)
Number of subjects: 35
Study 12950124 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic percutaneous cystostomy (17 patients)
Number of subjects: 35
Study 10391070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) at a dosage of 4 mg/kg/day
Number of subjects: 18
Study 10391070 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF) with one unit every third day for the first week, two units per week for the next three weeks, and one monthly unit for six months
Number of subjects: 18
Study 8748007 — intervention group
Group type: EXPERIMENTAL
Intervention: PLF (cisplatin or carboplatin, leucovorin, and 5-fluorouracil)
Number of subjects: 43
Study 8748007 — intervention group
Group type: EXPERIMENTAL
Intervention: PLEF (PLF + etoposide)
Number of subjects: 43
Study 2050157 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide cocktail (10 mg/kg) with betamethasone (20 mg) and biperiden (5 mg)
Number of subjects: 20
Study 2050157 — intervention group
Group type: COMPARATOR
Intervention: Dixyrazine combination (240 mg) with betamethasone (20 mg) and biperiden (5 mg)
Number of subjects: 20
Study 2050157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dixyrazine combination (240 mg)
Number of subjects: 20
Study 2050157 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide cocktail (10 mg/kg)
Number of subjects: 20
Study 6617071 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine sulfate, 60 mg
Number of subjects: 129
Study 6617071 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine sulfate, 120 mg
Number of subjects: 129
Study 6617071 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 650 mg
Number of subjects: 129
Study 6617071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 30654835 — intervention group
Group type: EXPERIMENTAL
Intervention: βHB mineral salt
Number of subjects: 45
Study 30654835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30409160 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram stain-guided initial antibiotic treatment
Number of subjects: 200
Study 30409160 — intervention group
Group type: COMPARATOR
Intervention: Guidelines-based initial antibiotic treatment
Number of subjects: 200
Study 30409160 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram stain-guided treatment
Number of subjects: 200
Study 30409160 — intervention group
Group type: COMPARATOR
Intervention: Guidelines-based treatment
Number of subjects: 200
Study 26179655 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Childhood Oral Health Impact Scale (ECOHIS)
Number of subjects: 189
Study 26179655 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOHIS
Number of subjects: 189
Study 25192851 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 618
Study 25192851 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg
Number of subjects: 618
Study 25192851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 22495093 — intervention group
Group type: EXPERIMENTAL
Intervention: Physio Acoustic Sound (PAS) therapy, applied for 30 minutes on a mattress with an in-built PAS device during the intervention period.
Number of subjects: 66
Study 22495093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PAS therapy), measurements continued without intervention during the wash-out period.
Number of subjects: 66
Study 20104935 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25-50 mg/day
Number of subjects: 4265
Study 20104935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4265
Study 20104935 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 4265
Study 17604563 — intervention group
Group type: EXPERIMENTAL
Intervention: LA (600 mg/day)
Number of subjects: 28
Study 17604563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 14988893 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 113
Study 14988893 — intervention group
Group type: EXPERIMENTAL
Intervention: Restenting (for focal ISR)
Number of subjects: 113
Study 14988893 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 113
Study 14988893 — intervention group
Group type: EXPERIMENTAL
Intervention: Restenting (for diffuse ISR)
Number of subjects: 113
Study 14988893 — intervention group
Group type: COMPARATOR
Intervention: Diffuse ISR (as a condition)
Number of subjects: 113
Study 11224984 — intervention group
Group type: EXPERIMENTAL
Intervention: New approaches to treatment based on immune system recognition of genetic alterations
Number of subjects: 0
Study 11224984 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of tumor development and genetic alterations
Number of subjects: 0
Study 9513327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial technique
Number of subjects: 40
Study 9513327 — intervention group
Group type: COMPARATOR
Intervention: Paresthesia technique
Number of subjects: 40
Study 7999408 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Number of subjects: 30
Study 7999408 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Number of subjects: 30
Study 7999408 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg fadrozole hydrochloride (CGS 169 49A) twice daily
Number of subjects: 30
Study 7999408 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg fadrozole hydrochloride (CGS 169 49A) daily
Number of subjects: 30
Study 7999408 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of fadrozole hydrochloride
Number of subjects: 30
Study 7999408 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 2494079 — intervention group
Group type: EXPERIMENTAL
Intervention: Uchida technique
Number of subjects: 20
Study 2494079 — intervention group
Group type: COMPARATOR
Intervention: Pomeroy technique
Number of subjects: 20
Study 1101363 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing dentifrices (0.1% and 0.4%)
Number of subjects: 73
Study 1101363 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrices
Number of subjects: 73
Study 31897933 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid ventricular pacing (RVP)
Number of subjects: 100
Study 31897933 — intervention group
Group type: COMPARATOR
Intervention: Control (no RVP)
Number of subjects: 100
Study 28776408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 10 treatments of invisible infrared laser (904 nm, 3 Joules/point) over three weeks followed by an eight-week supervised strengthening exercise program
Number of subjects: 40
Study 28776408 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT (identical treatment with disabled infrared laser output)
Number of subjects: 40
Study 26973326 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy with exercise (MT+Ex)
Number of subjects: 300
Study 26973326 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with boosters (Ex+B)
Number of subjects: 300
Study 26973326 — intervention group
Group type: COMPARATOR
Intervention: Exercise without boosters (Ex)
Number of subjects: 300
Study 26973326 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy with exercise without boosters (MT+Ex)
Number of subjects: 300
Study 26973326 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy with exercise with boosters (MT+Ex+B)
Number of subjects: 300
Study 26973326 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants receiving boosters
Number of subjects: 300
Study 26973326 — intervention group
Group type: COMPARATOR
Intervention: Participants not receiving boosters
Number of subjects: 300
Study 25535193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated scalpel harmonic ACE (Ethicon Endo‐Surgery)
Number of subjects: 164
Study 25535193 — intervention group
Group type: COMPARATOR
Intervention: Monopolar coagulation
Number of subjects: 164
Study 22759542 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO multimodal strategy with ABHR and powdered gloves
Number of subjects: 18669
Study 22759542 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO multimodal strategy with ABHR and powderless gloves
Number of subjects: 18669
Study 22759542 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18669
Study 22759542 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO multimodal strategy
Number of subjects: 18669
Study 20116457 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Medical Management (EMM; SMM plus individual drug counseling)
Number of subjects: 100
Study 20116457 — intervention group
Group type: COMPARATOR
Intervention: Standard Medical Management (SMM)
Number of subjects: 100
Study 20116457 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (bup/nx)
Number of subjects: 100
Study 18338152 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 W TULP (2.2 J, 18 Hz)
Number of subjects: 129
Study 18338152 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 W TULP (2.0 J, 12 Hz)
Number of subjects: 129
Study 18338152 — intervention group
Group type: COMPARATOR
Intervention: HoLEP (high-powered holmium laser enucleation)
Number of subjects: 129
Study 18338152 — intervention group
Group type: COMPARATOR
Intervention: TURP (transurethral resection of the prostate)
Number of subjects: 129
Study 16186674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral butorphanol 0.2 mg/kg
Number of subjects: 60
Study 16186674 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 60
Study 14514400 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH given from 7 - 9 PBD (T1)
Number of subjects: 40
Study 14514400 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH given from 10 - 14 PBD (T2)
Number of subjects: 40
Study 14514400 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 40
Study 10663451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg as single oral dose at 2200 hours)
Number of subjects: 6
Study 10663451 — intervention group
Group type: COMPARATOR
Intervention: No pantoprazole (baseline measurements)
Number of subjects: 6
Study 8880941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg nicotine
Number of subjects: 36
Study 8880941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg nicotine
Number of subjects: 36
Study 8880941 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 36
Study 2051404 — intervention group
Group type: EXPERIMENTAL
Intervention: Eusol dressings
Number of subjects: 75
Study 2051404 — intervention group
Group type: COMPARATOR
Intervention: Silastic foam dressings
Number of subjects: 75
Study 6341640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol treatment
Number of subjects: 16
Study 6341640 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study 31040088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol, 0.25 g/kg/h
Number of subjects: 52
Study 31040088 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 52
Study 31040088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 52
Study 28824019 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing training on both Day 1 and Day 2
Number of subjects: 0
Study 28824019 — intervention group
Group type: COMPARATOR
Intervention: Pinyin typing training on Day 1 and writing training on Day 2
Number of subjects: 0
Study 25619196 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational materials and follow-up questionnaire
Number of subjects: 641
Study 25619196 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's recommendation to be screened
Number of subjects: 641
Study 25619196 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of colon cancer
Number of subjects: 641
Study 25619196 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that health-care decisions should be mostly left to physicians
Number of subjects: 641
Study 24999797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 8 weeks
Number of subjects: 90
Study 24999797 — intervention group
Group type: COMPARATOR
Intervention: General information on IBS (Control)
Number of subjects: 90
Study 22250032 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG treatment after day 10
Number of subjects: 150
Study 22250032 — intervention group
Group type: COMPARATOR
Intervention: IVIG treatment before day 10 (control)
Number of subjects: 150
Study 20357281 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg daily)
Number of subjects: 6729
Study 20357281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6729
Study 17350069 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial training session
Number of subjects: 0
Study 17350069 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-trial interval longer than 3s
Number of subjects: 0
Study 17350069 — intervention group
Group type: EXPERIMENTAL
Intervention: New locations for targets within the texture stimulus
Number of subjects: 0
Study 17350069 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-irrelevant targets
Number of subjects: 0
Study 15709841 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral couple therapy for infidelity couples
Number of subjects: 19
Study 12144005 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow sheet intervention incorporating GINA guidelines
Number of subjects: 122
Study 9486164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg)
Number of subjects: 7
Study 9486164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8566638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine 0.02 mg/kg (maximum 0.4 mg)
Number of subjects: 101
Study 8566638 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 101
Study 8566638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine with meperidine
Number of subjects: 101
Study 8566638 — intervention group
Group type: COMPARATOR
Intervention: Meperidine with placebo
Number of subjects: 101
Study 3123222 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 24
Study 3123222 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 24
Study 3123222 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24
Study 29685048 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-cytology brush (EUS-EB)
Number of subjects: 65
Study 29685048 — intervention group
Group type: COMPARATOR
Intervention: EUS-fine needle aspiration (EUS-FNA)
Number of subjects: 65
Study 27168266 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5mg BID
Number of subjects: 1843
Study 27168266 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10mg BID
Number of subjects: 1843
Study 27168266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1843
Study 24993458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care from a clinical pharmacist
Number of subjects: 733
Study 24993458 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care (control)
Number of subjects: 733
Study 22683276 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% topical clonidine gel applied 3 times a day for 12 weeks
Number of subjects: 179
Study 20404228 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive fractional radiofrequency (FRF) treatment
Number of subjects: 15
Study 20404228 — intervention group
Group type: COMPARATOR
Intervention: Surgical face-lift
Number of subjects: 15
Study 19189673 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 0
Study 19189673 — intervention group
Group type: EXPERIMENTAL
Intervention: Clerafil Tri-S Bond
Number of subjects: 0
Study 19189673 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond
Number of subjects: 0
Study 19189673 — intervention group
Group type: COMPARATOR
Intervention: Caries-affected dentin
Number of subjects: 0
Study 19189673 — intervention group
Group type: COMPARATOR
Intervention: Normal dentin
Number of subjects: 0
Study 19164270 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity counseling (single session + supportive phone contact every 4 months for 2 years)
Number of subjects: 632
Study 19164270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 632
Study 15257052 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 100
Study 15257052 — intervention group
Group type: COMPARATOR
Intervention: Atgam
Number of subjects: 100
Study 11599643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine maintenance treatment during a 62-week study
Number of subjects: 55
Study 9480606 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endoprosthetic replacement
Number of subjects: 30
Study 9480606 — intervention group
Group type: COMPARATOR
Intervention: Minimal osteosynthesis
Number of subjects: 30
Study 8281707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure FSH (225 IU/day)
Number of subjects: 34
Study 8281707 — intervention group
Group type: COMPARATOR
Intervention: hMG (225 IU/day)
Number of subjects: 34
Study 3321539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8
Study 3321539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11740220 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 18
Study 11740220 — intervention group
Group type: COMPARATOR
Intervention: Unoprostone 0.12%
Number of subjects: 18
Study 30325696 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Physical Effort (APE) - 30-min walk at 65%-75% of age-predicted maximal HR
Number of subjects: 14
Study 30325696 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Orthostatic Position (AS) - changing from supine to standing position
Number of subjects: 14
Study 30325696 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - healthy volunteers
Number of subjects: 14
Study 28860019 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin
Number of subjects: 2286
Study 28860019 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2286
Study 27067479 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 396
Study 24473534 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 54
Study 24473534 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and wellness education (HW)
Number of subjects: 54
Study 24473534 — intervention group
Group type: COMPARATOR
Intervention: Wait list (WL)
Number of subjects: 54
Study 22695403 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap-and-water body wipes
Number of subjects: 151
Study 22695403 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol (IPA) body wipes
Number of subjects: 151
Study 22695403 — intervention group
Group type: COMPARATOR
Intervention: No treatment (CONTROL)
Number of subjects: 151
Study 20360542 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroidism patients
Number of subjects: 3176
Study 20360542 — intervention group
Group type: COMPARATOR
Intervention: Comparison cohort (without hyperthyroidism)
Number of subjects: 3176
Study 17409767 — intervention group
Group type: EXPERIMENTAL
Intervention: High dialysate calcium (HdCa) concentration of 1.75 mmol/l
Number of subjects: 14
Study 17409767 — intervention group
Group type: COMPARATOR
Intervention: Low dialysate calcium (LdCa) concentration of 1.25 mmol/l
Number of subjects: 14
Study 14670399 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 106
Study 14670399 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 106
Study 14670399 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 11779668 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg or 2 mg of oral naloxone, three times daily
Number of subjects: 9
Study 11779668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9